Information Provided By:
Fly News Breaks for December 7, 2015
BLUE
Dec 7, 2015 | 06:35 EDT
Morgan Stanley analyst Matthew Harrison downgraded bluebird to Equal Weight and lowered his price target to $69 from $143 on shares following updated data from ASH. Harrison said the updated sickle cell data indicates more work is necessary before potential cures can be achieved and reduced his expected price and penetration for BB305, and pushed out the launch date to 2021 from 2020.